Company news

Regen Biopharma, Inc. (OTC:RGBP) news

Regen Biopharma, Inc. news releases on 6ix. Latest, Jan 20, 2026: Presenting on Emerging Growth Conference 89 Day 1 on January 21; Register to live stream

Regen Biopharma, Inc. (OTC:RGBP) news

Press releases & updates

Presenting on Emerging Growth Conference 89 Day 1 on January 21; Register to live stream

Presenting on Emerging Growth Conference 88 Day 1 on December 10; Register to live stream

Goldman Small Cap Research Publishes New Research Report on Regen BioPharma, Inc.

Presenting on Emerging Growth Conference 87 Day 2 on October 23; Register to live stream

Regen BioPharma Update on Orphan Drug Application for HemaXellerate Will Be Presented At Emerging Growth Conference on September 24, 2025

Presenting on Emerging Growth Conference 86 Day 1 on September 24; Register to live stream

Regen BioPharma Prepares Response For FDA Regarding Its Orphan Drug Application for HemaXellerate

Regen BioPharma Explores Expanded Use of HemaXellerate for Chemotherapy-Induced Bone Marrow Suppression

Presenting on Emerging Growth Conference 85 Day 1 on August 20; Register to live stream

Regen BioPharma Discusses Potential Impact of HemaXellerate on Chemotherapy Treament Market

Regen BioPharma, Inc. to Seek Orphan Drug Designation for Lead Product

Presenting on Emerging Growth Conference 83 Day 2 on June 18; Register to live stream

Presenting on Emerging Growth Conference 82 Day 2 on May 22; Register to live stream

Presenting on Emerging Growth Conference 81 Day 2 on April 17; Register to live stream

Presenting on the Emerging Growth Conference 80 Day 2 on March 27 Register Now

Presenting on the Emerging Growth Conference 79 Day 1 on February 18 Register Now

Regen BioPharma, Inc. Responds to Fake News Release

Regen BioPharma, Inc. Examines Combining Cannabidiol (CBD) With Its Lead NR2F6 Agonist To Treat for Inflammatory Bowel Disease

Regen BioPharma, Inc. Reports Additional New NR2F6 Small Molecule Inhibitors

Regen BioPharma, Inc. Determines Its Lead NR2F6 Agonist Ready for Inflammatory Bowel Disease Animal Studies

Regen BioPharma, Inc. Reports Activation of Immune Cells by Its NR2F6 Small Molecule Inhibitors

Regen BioPharma, Inc. Updates Report on Success of Its NR2F6 Small Molecule Antagonist Screening Program for Treating Cancer

Regen BioPharma, Inc. Files New Composition of Matter Patent Application Based on Its Successful Modulation of NR2F6 by Its Small Molecule Compounds

Regen BioPharma, Inc. Reports Success of its NR2F6 Small Molecule Screening Program for Treating Autoimmune Diseases

No Toxicity Seen in Mice as Regen BioPharma, Inc. Finishes Initial Optimization of its Lead NR2F6 Small Molecule Agonist

Regen BioPharma, Inc. Nears Completion of Optimizing its Lead NR2F6 Small Molecule Agonist

Regen BioPharma, Inc. Program to Determine the 3-D Crystal Structure of NR2F6 Progresses to Next Step

Regen BioPharma, Inc.'s Medicinal Chemistry Program has Identified Additional Compounds That Activate NR2F6

Regen BioPharma, Inc. Files Additional Composition of Matter Patent Application on NR2F6-Modulating Small Molecules

Regen BioPharma, Inc. Begins In Vivo Assessment of Small Molecule Agonists to NR2F6 Nuclear Receptor

Regen BioPharma Inc. Chairman Discusses the Rationale for Pursuing Autoimmune Indications by Activating the Nuclear Receptor NR2F6

Regen BioPharma's Chief Scientific Officer Explains the Link Between its NR2F6 Medicinal Chemistry and Three-Dimensional X-Ray Structure Programs

Regen BioPharma, Inc. Announces Former Eli Lilly Executive and Current CVS Board Member will Lead Newly Formed Business Advisory Board (BAB)

Regen BioPharma, Inc. Begins Program to Determine the 3-Dimensional Crystal Structure of NR2F6

Regen BioPharma, Inc. Researchers Capitalize on Key Structure in Compounds that Activate Checkpoint NR2F6 for the Potential Treatment of Autoimmune Diseases

Regen BioPharma, Inc. Researchers Demonstrate Direct Binding of Proprietary Agonists to Immune Checkpoint NR2F6

Regen BioPharma Issues End of Fiscal Year Shareholder Letter

Regen BioPharma, Inc. Researchers Identify Key Structure in Compounds that Activate NR2F6

Regen BioPharma, Inc. Addresses Potential Impact of Recent Bristol Myers Squibb's $2.3 Billion Acquisition of IFM Therapeutics

Regen BioPharma, Inc. Addresses Potential Impact of Recent Bristol Myers Squibb $2.3 Billion Acquisition of IFM Therapeutics

Regen BioPharma, Inc. Research Demonstrates Ex-Vivo Immune Suppression With Novel NR2F6 Activators

Regen BioPharma, Inc. Researchers Discover New Dynamic Compound Which Modulates the NR2F6 Checkpoint

Regen BioPharma, Inc. Sees Additional Positive Results on its Medicinal Chemistry Optimization for Modulating NR2F6 Checkpoint for Treating Cancer and Autoimmune Diseases

Regen BioPharma, Inc. Identifies Three New Series of Compounds That Activate NR2F6

Regen BioPharma, Inc. Sees Success in Its Pre-Clinical Small Molecule Optimization Program for NR2F6

Regen BioPharma, Inc. Provides Update on NR2F6 Small Molecule Optimization Program for Treating Cancer and Arthritis

Regen BioPharma Restructures Management Stock Compensation

Regen BioPharma, Inc. Licenses NR2F6 Technology for Cancer Treatment and Autoimmune Disorders to CheckPoint Immunology Inc.

Regen BioPharma Begins Optimization of NR2F6 Small Molecule Modulators

Regen BioPharma, Inc. Files Utility Patent Application on NR2F6-Silenced CAR-T Cell for Solid Tumors